|
YWHAH expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.54290050022621E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.0557999746984E-09 |
| Normal-vs-Stage2 |
1.090640E-01 |
| Normal-vs-Stage3 |
1.39600000448326E-08 |
| Normal-vs-Stage4 |
3.88380000004851E-06 |
| Stage1-vs-Stage2 |
6.742300E-03 |
| Stage1-vs-Stage3 |
1.907420E-01 |
| Stage1-vs-Stage4 |
4.113000E-01 |
| Stage2-vs-Stage3 |
3.184300E-03 |
| Stage2-vs-Stage4 |
8.881100E-03 |
| Stage3-vs-Stage4 |
8.032600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.37150349042304E-11 |
| Normal-vs-AfricanAmerican |
6.740100E-03 |
| Normal-vs-Asian |
1.51867000000028E-05 |
| Caucasian-vs-AfricanAmerican |
8.273600E-01 |
| Caucasian-vs-Asian |
6.573000E-01 |
| AfricanAmerican-vs-Asian |
6.513800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.47539999995061E-06 |
| Normal-vs-Female |
3.35440009102683E-10 |
| Male-vs-Female |
4.411200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.11379999562433E-09 |
| Normal-vs-Age(41-60Yrs) |
1.8224999953631E-08 |
| Normal-vs-Age(61-80Yrs) |
5.393200E-04 |
| Normal-vs-Age(81-100Yrs) |
1.506140E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.210400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.130040E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.635600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.278200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.103200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.288400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.782100E-04 |
| Classical-VS-Follicular |
1.62503344114384E-12 |
| Classical-VS-Other |
2.372200E-01 |
| Classical-VS-Normal |
2.35245156687824E-12 |
| Tall-VS-Follicular |
6.77690004113884E-09 |
| Tall-VS-Other |
2.237800E-02 |
| Tall-VS-Normal |
1.02130000012579E-08 |
| Follicular-VS-Other |
1.415360E-01 |
| Follicular-VS-Normal |
8.692600E-01 |
| Other-VS-Normal |
3.333400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.020820E-04 |
| Normal-vs-N1 |
1.80220999999037E-05 |
| N0-vs-N1 |
4.955800E-02 |
|
|
